PANACEA was a single-arm, phase 1b-2 study in which patients with trastuzumab-resistant advanced breast cancer were treated with the programmed cell death 1 (PD1) inhibitor pembrolizumab in combination with trastuzumab [90]. Here, PDCD1 is linked to breast carcinoma.